Gilbert M. Rishton
biomedical
pharmaceutical
CARDAX COMPANY
Haiti
Biography
Gilbert M. Rishton, Ph.D. has led drug discovery programs in the pharmaceutical industry for over fifteen years, primarily at Amgen. He was the founding medicinal chemist at Amgen’s Thousand Oaks site, and was repsonsible for initiating and building the Amgen Small Molecule Drug Discovery Group, which has grown to become one of the most formidable in the pharmaceutical industry. He was also the chemistry manager for Amgen’s Sensipar development program, which spanned several phases from preclinical development to manufacturing and then human clinical trials, resulting in the commercial launch of Sensipar, Amgen’s first orally administered small molecule product. He also led the medicinal chemistry program for Amgen’s Secretase Team, which was among the first to produce small molecule secretase inhibitors as potential therapeutic agents for Alzheimer’s disease.
Research Interest
Gilbert M. Rishton, Ph.D. has led drug discovery programs in the pharmaceutical industry for over fifteen years, primarily at Amgen. He was the founding medicinal chemist at Amgen’s Thousand Oaks site, and was repsonsible for initiating and building the Amgen Small Molecule Drug Discovery Group, which has grown to become one of the most formidable in the pharmaceutical industry. He was also the chemistry manager for Amgen’s Sensipar development program, which spanned several phases from preclinical development to manufacturing and then human clinical trials, resulting in the commercial launch of Sensipar, Amgen’s first orally administered small molecule product. He also led the medicinal chemistry program for Amgen’s Secretase Team, which was among the first to produce small molecule secretase inhibitors as potential therapeutic agents for Alzheimer’s disease.
